Immunservice GmbH, a Hamburg, Germany-based company that develops biological medicines, closed a Series C round of financing of undisclosed amount.
Dr. Michael Otto, entrepreneur and Chairman of the Board at the Otto Group, joined Helmut Ponath, the Hubertus-Wald-Stiftung, the High-Tech-Gründerfonds (HTGF) and Hartwig Huland.
The company intends to use the funds to advance its biological immunotherapy methods.
Led by Edith Huland (CEO) and Conny Cloppenburg (CFO), Immunservice develops biological medicines that activate the body’s own immune system to eliminate cancer and viral infections.
A key function in this immune defense is performed by Interleukin-2, an essential immune hormone that occurs naturally in the body.
The company produces Interleukin-2 for pharmaceutical development in a form suitable for special applications.
The focus is on renal cancer and melanoma.